Loading organizations...

§ Private Profile · San Francisco, CA, USA
Mekonos is a company.
Mekonos has raised $30.6M across 3 funding rounds.
Key people at Mekonos.
Mekonos has raised $30.6M in total across 3 funding rounds.
Mekonos develops a proprietary cell-engineering platform utilizing scalable silicon technology. This platform aims to accelerate breakthroughs in cell and gene therapies and streamline cell line development. Its technical approach leverages semiconductor, MEMS, and microfluidics expertise to enable precise and efficient genetic manipulation on a chip.
The company was founded in 2017. Its inception stemmed from the vision of co-founders Steven Banerjee, Anil Narasimha, and Greg Sitters, who identified a critical need for more scalable and precise cell engineering solutions. Their combined expertise in biotechnology and silicon-based technologies informed the development of a unique approach to addressing these challenges.
Mekonos targets partners actively engaged in developing advanced cell and gene therapies, as well as those focused on cell line development. The company's long-term vision centers on building the future of cell therapies on a chip, fundamentally transforming synthetic biology and advancing personalized medicine through its innovative platform.
Key people at Mekonos.
Mekonos has raised $30.6M across 3 funding rounds. Most recently, it raised $25.0M Series A in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 10, 2021 | $25M Series A | Lambert Potin, Elementum Ventures, Fiscus Ventures, Novartis Pharma, PEAK6 Strategic Capital, Reimagined Ventures, Sands Capital, Section 32, Nicolas Sauvage | — | Announced |
| Dec 4, 2020 | $4.6M Venture Round | Novartis | CRCM Ventures, Elementum Ventures, Good AI Capital, Hike Ventures | Announced |
| Jun 1, 2018 | $1M Seed | — | BoxOne Ventures | Announced |
Mekonos has raised $30.6M in total across 3 funding rounds.
Mekonos's investors include Lambert Potin, Elementum Ventures, Fiscus Ventures, Novartis Pharma, PEAK6 Strategic Capital, Reimagined Ventures, Sands Capital, Section 32, Nicolas Sauvage, Novartis, CRCM Ventures, Good AI Capital.
Mekonos is a San Francisco–based biotech company that built a proprietary “cell‑on‑a‑chip” platform (a MEMS + microfluidics SoC) to deliver molecular cargo into individual cells for cell and gene therapy development and personalized medicine, and it raised a $25M Series A in 2021 before ceasing operations in 2024[2][1][5].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
If you’d like, I can: